×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
UTHR – united therapeutics corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
UTHR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
11:28 am
uthr
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]
Neutral
Report
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]
11/13
09:00 am
uthr
Maryland Businesses Celebrate Expansions, Promotions and Milestones
Low
Report
Maryland Businesses Celebrate Expansions, Promotions and Milestones
11/5
04:30 pm
uthr
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
Medium
Report
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
11/4
06:17 pm
uthr
Metro Aviation Orders BETA Technologies' eVTOL for Medical Transport [Yahoo! Finance]
Medium
Report
Metro Aviation Orders BETA Technologies' eVTOL for Medical Transport [Yahoo! Finance]
11/4
11:43 am
uthr
United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy? [Yahoo! Finance]
Low
Report
United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy? [Yahoo! Finance]
11/4
07:38 am
uthr
The leading LLMs have accessibility blind spots, says data from startup Evinced [Fortune]
Low
Report
The leading LLMs have accessibility blind spots, says data from startup Evinced [Fortune]
11/1
01:38 pm
uthr
United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $243.00 to $302.00. They now have a "neutral" rating on the stock.
Low
Report
United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $243.00 to $302.00. They now have a "neutral" rating on the stock.
11/1
11:55 am
uthr
United Therapeutics Q3 Earnings & Sales Beat Estimates [Yahoo! Finance]
Low
Report
United Therapeutics Q3 Earnings & Sales Beat Estimates [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2024
06:30 am
uthr
united therapeutics corporation
BEAT
Report
1.8%
united therapeutics corporation
7/31/2024
06:30 am
uthr
united therapeutics corporation
MISS
Report
-8.9%
united therapeutics corporation
5/1/2024
06:30 am
uthr
united therapeutics corporation
BEAT
Report
8.4%
united therapeutics corporation
2/21/2024
06:00 am
uthr
united therapeutics corporation
BEAT
Report
6.9%
united therapeutics corporation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
04:30 pm
uthr
Form 4 UNITED THERAPEUTICS Corp For: Nov 18 Filed by: BENKOWITZ MICHAEL
Low
Report
Form 4 UNITED THERAPEUTICS Corp For: Nov 18 Filed by: BENKOWITZ MICHAEL
11/18
05:04 pm
uthr
Form 144 UNITED THERAPEUTICS Corp Filed by: BENKOWITZ MICHAEL
Low
Report
Form 144 UNITED THERAPEUTICS Corp Filed by: BENKOWITZ MICHAEL
11/12
04:31 pm
uthr
Form 4 UNITED THERAPEUTICS Corp For: Nov 08 Filed by: Mesa Nilda
Low
Report
Form 4 UNITED THERAPEUTICS Corp For: Nov 08 Filed by: Mesa Nilda
11/12
04:31 pm
uthr
Form 4 UNITED THERAPEUTICS Corp For: Nov 11 Filed by: BENKOWITZ MICHAEL
Low
Report
Form 4 UNITED THERAPEUTICS Corp For: Nov 11 Filed by: BENKOWITZ MICHAEL
11/12
04:31 pm
uthr
Form 4 UNITED THERAPEUTICS Corp For: Nov 11 Filed by: Olian Judy D.
Low
Report
Form 4 UNITED THERAPEUTICS Corp For: Nov 11 Filed by: Olian Judy D.
11/12
11:33 am
uthr
Form 144 UNITED THERAPEUTICS Corp Filed by: Olian Judy D.
Low
Report
Form 144 UNITED THERAPEUTICS Corp Filed by: Olian Judy D.
11/8
04:32 pm
uthr
Form SC 13G/A UNITED THERAPEUTICS Corp Filed by: ROTHBLATT MARTINE A
Low
Report
Form SC 13G/A UNITED THERAPEUTICS Corp Filed by: ROTHBLATT MARTINE A
11/8
04:32 pm
uthr
Form 4 UNITED THERAPEUTICS Corp For: Nov 07 Filed by: MAHON PAUL A
Low
Report
Form 4 UNITED THERAPEUTICS Corp For: Nov 07 Filed by: MAHON PAUL A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/10
Jefferines likes United Therapeutics in premarket analyst action [Seeking Alpha]
8.4%
2/24 United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints 7.8%
3/27 Form 4 UNITED THERAPEUTICS Corp For: Mar 25 Filed by: SULLIVAN LOUIS W 5.9%
3/18 Form 4 UNITED THERAPEUTICS Corp For: Mar 17 Filed by: PATUSKY CHRISTOPHER 5.3%
6/28 Form 4 UNITED THERAPEUTICS Corp For: Jun 26 Filed by: Mesa Nilda 5.1%
2/4 United Therapeutics Defeats Preliminary Injunction Motion In Litigation With Sandoz And RareGen 5.0%
8/1 United Therapeutics Corporation (UTHR) 2019 Q2 Earnings Call Transcript [The Motley Fool] 4.8%
3/24 Form 4 UNITED THERAPEUTICS Corp For: Mar 23 Filed by: SULLIVAN LOUIS W 4.3%
4/21 Form 4 UNITED THERAPEUTICS Corp For: Apr 20 Filed by: Giltner Richard 3.9%
1/28 United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $237.00 price target on the stock. 3.5%
2/24 United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints 7.8%
3/27 Form 4 UNITED THERAPEUTICS Corp For: Mar 25 Filed by: SULLIVAN LOUIS W 5.9%
3/18 Form 4 UNITED THERAPEUTICS Corp For: Mar 17 Filed by: PATUSKY CHRISTOPHER 5.3%
6/28 Form 4 UNITED THERAPEUTICS Corp For: Jun 26 Filed by: Mesa Nilda 5.1%
2/4 United Therapeutics Defeats Preliminary Injunction Motion In Litigation With Sandoz And RareGen 5.0%
8/1 United Therapeutics Corporation (UTHR) 2019 Q2 Earnings Call Transcript [The Motley Fool] 4.8%
3/24 Form 4 UNITED THERAPEUTICS Corp For: Mar 23 Filed by: SULLIVAN LOUIS W 4.3%
4/21 Form 4 UNITED THERAPEUTICS Corp For: Apr 20 Filed by: Giltner Richard 3.9%
1/28 United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $237.00 price target on the stock. 3.5%
TOP News Decliners
2/26
Q4/2019 12/31/2019 EPS 1.960 ZacksConsensus 2.470 ActVsEst (0.510) - Miss
-6.2%
2/27 United Therapeutics Co. (NASDAQ: UTHR) was upgraded by analysts at Cowen Inc from a "market perform" rating to an "outperform" rating. -4.7%
12/13 Form 8-K UNITED THERAPEUTICS Corp For: Dec 13 -4.1%
6/13 Form 4 UNITED THERAPEUTICS Corp For: Jun 13 Filed by: Giltner Richard -3.5%
6/5 United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference -3.4%
10/30 How United Therapeutics Trounced Wall Street's Q3 Estimates [The Motley Fool] -3.1%
2/25 United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $243.00 price target on the stock. -3.0%
12/3 United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -2.8%
6/11 United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.5%
2/3 United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint -2.2%
2/27 United Therapeutics Co. (NASDAQ: UTHR) was upgraded by analysts at Cowen Inc from a "market perform" rating to an "outperform" rating. -4.7%
12/13 Form 8-K UNITED THERAPEUTICS Corp For: Dec 13 -4.1%
6/13 Form 4 UNITED THERAPEUTICS Corp For: Jun 13 Filed by: Giltner Richard -3.5%
6/5 United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference -3.4%
10/30 How United Therapeutics Trounced Wall Street's Q3 Estimates [The Motley Fool] -3.1%
2/25 United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $243.00 price target on the stock. -3.0%
12/3 United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -2.8%
6/11 United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.5%
2/3 United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint -2.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: